Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 33.43 USD 0.66% Market Closed
Market Cap: 3.2B USD

Wall Street
Price Targets

RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc

Wall Street analysts forecast RARE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RARE is 83.74 USD with a low forecast of 35.35 USD and a high forecast of 134.4 USD.

Lowest
Price Target
35.35 USD
6% Upside
Average
Price Target
83.74 USD
150% Upside
Highest
Price Target
134.4 USD
302% Upside
Ultragenyx Pharmaceutical Inc Competitors:
Price Targets
ZNTL
Zentalis Pharmaceuticals Inc
304% Upside
302440
SK Bioscience Co Ltd
22% Downside
OPK
OPKO Health Inc
186% Upside
DVYSR
Devyser Diagnostics AB
54% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
51% Upside
CANTA
Cantargia AB
115% Upside
2162
KeyMed Biosciences Inc
58% Upside
PEB
Pacific Edge Ltd
20% Downside

Revenue
Forecast

Revenue Estimate
Ultragenyx Pharmaceutical Inc

The compound annual growth rate of Ultragenyx Pharmaceutical Inc's revenue for the next 4 years is 29%.

N/A
Past Growth
29%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ultragenyx Pharmaceutical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Ultragenyx Pharmaceutical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RARE's stock price target?
Price Target
83.74 USD

According to Wall Street analysts, the average 1-year price target for RARE is 83.74 USD with a low forecast of 35.35 USD and a high forecast of 134.4 USD.

What is Ultragenyx Pharmaceutical Inc's Revenue forecast?
Projected CAGR
29%

The compound annual growth rate of Ultragenyx Pharmaceutical Inc's revenue for the next 4 years is 29%.

Back to Top